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The importance of adolescent engagement in health decisions and public health programs
such as immunisation is becoming increasingly recognised. Understanding adolescent pref-
erences and further identifying barriers and facilitators for immunisation acceptance is criti-
cal to the success of adolescent immunisation programs. This study applied a discrete
choice experiment (DCE) to assess vaccination preferences in adolescents.
Methods
This study was conducted as a cross-sectional, national online survey in Australian adoles-
cents. The DCE survey evaluated adolescent vaccination preferences. Six attributes were
assessed including disease severity, target for protection, price, location of vaccination pro-
vision, potential side effects and vaccine delivery method. A mixed logit model was used to
analyse DCE data.
Results
This survey was conducted between December 2014 and January 2015. Of 800 adoles-
cents aged 15 to 19 years, stronger preferences were observed overall for: vaccination in
the case of a life threatening illness (p<0.001), lower price vaccinations (p<0.001), mild but
common side effects (p = 0.004), delivery via a skin patch (p<0.001) and being administered
by a family practitioner (p<0.001). Participants suggested that they and their families would
be willing to pay AU$394.28 (95%CI: AU$348.40 to AU$446.92) more for a vaccine target-
ing a life threatening illness than a mild-moderate illness, AU$37.94 (95%CI: AU$19.22 to
AU$57.39) more for being vaccinated at a family practitioner clinic than a council immunisa-
tion clinic, AU$23.01 (95%CI: AU$7.12 to AU$39.24) more for common but mild and
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resolving side effects compared to rare but serious side effects, and AU$51.80 (95%CI: AU
$30.42 to AU$73.70) more for delivery via a skin patch than injection.
Conclusions
Consideration of adolescent preferences may result in improved acceptance of, engage-
ment in and uptake of immunisation programs targeted for this age group.
Introduction
Adolescence is a time in life that often features risk taking behaviours, however it also provides
the greatest opportunity for sustained wellbeing into adulthood. Although adolescents are
often treated as younger adults, their views and values are typically overlooked when public
health strategies that affect them are being designed.
One of these strategies is immunisation, with adolescents an increasingly important target
group for immunisation internationally [1]. Routine immunisation of adolescents provides
individual protection and herd protection against vaccine-preventable diseases such as
Human Papillomavirus (HPV) and meningococcal disease, boosts the pre-existing but waning
immunity (e.g. diphtheria/tetanus/pertussis booster vaccination) and delivers catch-up pro-
grams for those who did not receive recommended vaccines during childhood [2]. However,
compared to infant and childhood immunisation, the current adolescent immunisation cover-
age is suboptimal with uptake rates varying between 50% and 80% in high resource countries
(e.g. Australia [3] and the United States [4]). Lack of awareness of vaccination recommenda-
tions, concerns about vaccine side effects, confusion over immunisation schedules and not
actively attending preventive health visits could be barriers to vaccinating adolescents [5, 6].
However, earlier studies in this area have mainly focused on parental or adult preferences for
immunisation or on a specific vaccine, such as for HPV, for adolescents [7–13]. Since there is
an evidence base to indicate that adolescents are willing to be involved and their attitudes can
significantly affect parents’ vaccination decisions [5, 14, 15], adolescent immunisation uptake
could be improved through better understanding adolescent preferences for vaccination.
Understanding their preferences is also important for the development of any vaccination edu-
cation programs. Such programs can overcome vaccine hesitancy or refusal, and can also pro-
vide vaccine providers and health authorities with useful information to inform policy prior to
the introduction of any future targeted adolescent vaccine programs.
Discrete choice experiments (DCEs) are commonly used in health economics to elicit par-
ticipants’ preferences for healthcare programs and policies. The technique uses an attribute
based quantitative survey method and draws on elements of random utility theory, consumer
theory, and experimental design theory. In DCEs, a number of salient attributes are used to
describe characteristics of interventions, and each attribute takes a range of levels. The value
(utility) of each scenario is determined by different levels of attributes. Participants trade off
risks and benefits among alternative scenarios and express their preferences by choosing their
preferred option [16, 17]. Where price is included as an additional attribute, the DCE
approach may also be used to estimate individuals’ willingness to pay (WTP) for healthcare
interventions [16]. Immunisation acceptance by adolescents may be influenced by a number
of factors including severity of illness, side effects, out-of-pocket costs, healthcare facilities
where vaccines are administered, mode of administration, vaccine effectiveness and duration
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of immunity [9, 12]. Adolescents may choose to trade off the potential health benefits against
perceived drawbacks of immunisation in the decision making dynamic.
An adolescent-friendly approach, which includes eliciting adolescent views on public health
programs that we expect them to engage in, is required if we aim to reduce the barriers to tak-
ing part in such programs. Several different methodologies including DCEs have been used
previously to assess adolescent values of health states [18, 19]. However, a limited amount of
research has been conducted to date to assess adolescent preferences and attitudes towards
immunisation program delivery [14, 20–22]. Using an online DCE, this study aimed to investi-




This survey was conducted according to guidelines for the design and conduct of DCE studies
in healthcare [17, 23–25].
For this study, it was important to identify a number of relevant and generic attributes that
enable participants to make a meaningful judgment regarding adolescent preferences for
immunisation. We considered a literature review and expert opinion (interview with a clini-
cian in child and adolescent health and vaccinologist, a health economist/DCE expert, an ethi-
cist and an adolescent health researcher) as the appropriate sources of information. A rapid
systematic review was performed by searching titles and abstracts in the PubMed database for
DCE studies investigating vaccines preferences. Experts were asked to review the list of attri-
butes derived from the literature review, and the following were identified as appropriate to
include in our DCE: disease target [26–29], location of vaccination [9, 13, 30, 31], potential for
side effects [8–10, 13, 30–35], vaccine delivery mechanism [10] and price [9, 10, 13, 30, 31, 35,
36]. Since herd protection is an important factor affecting acceptance of vaccines and out-
comes of cost-effectiveness evaluations [37], “target for protection” was also added to the attri-
bute list based on the expert opinion. The levels of each attribute were selected as to whether
they were plausible and relevant from both the clinical and the policy viewpoint. Based on the
range of private vaccine prices in Australia (approximately AU$ 30–200 per dose) and assump-
tion of at least three doses required, price levels of AU$100 and AU$500 were chosen in addi-
tion to publicly-funded free vaccination. A previous DCE study found the adolescents’
personal financial situation was significantly associated with their vaccination choice rather
than their household financial situation [7]. Considering some adolescents might have already
worked full or part-time, we used the term “cost to self (or family)”. Vaccine efficacy was
selected as an attribute in a number of previous DCE studies [8–10, 13, 26–34], but not
included in our DCE survey as it was not reported as a major contributor to vaccine hesitancy
or refusal [38, 39]. Previous research found participants’ decisions to vaccinate were not sensi-
tive to the probability of disease [35]. Therefore neither disease prevalence nor incidence were
included in order to reduce participants’ cognitive burden.
A D-efficient (Dz-error, i.e. zero priors assumed for all variables) design, for main effects
only, was developed using Ngene 1.1.2 [40], which yielded 36 choice sets that were further
divided into three blocks so as to minimise participants’ cognitive burden. Each participant
was randomly assigned to one of the three blocks. One choice question in each block was
repeated to check for internal consistency. An example of a choice question is shown in
Table 1. Before participants were asked to make a choice between options A or B for each
choice question, a detailed explanation of how to choose between alternatives was presented.
The possible differences in each hypothetical scenario were listed: 1) disease targeted including
Assessing vaccine preferences in adolescents
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mild-moderate illness (unlikely to be fatal), life threatening illness (could be fatal), sexually
transmitted infection, or chronic illness; 2) target for protection including the individual
(you)–being vaccinated will provide protection against disease affecting adolescents and
young adults, or the individual (you) and others–being vaccinated will protect the individual
(you) and others by reducing spread of disease to others in the community; 3) price including
$0, $100, or $500; 4) setting (location of vaccination) including school/university, GP (i.e. fam-
ily practitioner), or council immunisation clinic; 5) potential for side effects including rare
(1:100,000) but serious (i.e. allergic reaction), or common but mild and resolving (i.e. fever,
local redness or swelling); 6) vaccine delivery mechanism including injection (needle), skin
patch, or oral dose.
The questionnaire included a series of socio-demographic questions and 13 DCE choice
questions. In addition, two questions in relation to attitudes towards risk in general or with
health were measured on an eleven point scale, with zero indicating “not at all prepared to take
risk”, and ten indicating “very much prepared to take risk” [41] to assess risk taking
behaviours.
The draft survey questionnaire was pre-piloted with a convenience sample of three adoles-
cents and only minor changes were made to ensure adolescents could interpret all questions
appropriately. The survey was also pilot tested in 130 participants with approximately 43 par-
ticipants per block to check feasibility and internal consistency. Seventeen participants (13.1%)
failed the internal consistency test. Since the inconsistency rate was comparable to that
reported in previous DCE studies [42, 43], no revisions were made to the DCE survey.
Sample size and study population
Calculation of optimal sample sizes is complex as it depends on the true values of the unknown
parameters estimated in the DCE models [17]. However, as a rule of thumb suggested by
Orme [44], a sample size of 300 would be desirable for a main effects model based on the num-
ber of choice sets, alternatives and analysis cells. We aimed to recruit 20 participants per choice
set resulting in 720 adolescents aged between 15–19 years, which would provide more
Table 1. Example of a DCE question. Please consider that you are making a choice about receiving a vac-
cine/s for yourself. Of the options in the table below (A or B), please select which option you would choose.
Considering the possible scenarios outlined below, which option would you choose?
Features Option A Option B
Disease targeted Chronic illness Mild-moderate illness (unlikely to be
fatal)
Target for protection The individual (you)–being vaccinated
will provide protection against disease
affecting adolescents and young adults
The individual (you) and others–being
vaccinated will protect the individual
(you) and others by reducing spread of
disease to others in the community
Cost to self (or family) $500 $100
Location of
vaccination
General practitioner (GP) School/University
Potential for side
effects
Common but mild and resolving (i.e.
fever, local redness or swelling)




Oral dose Skin patch
Which option would
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statistical power with a sample size larger than in similar adolescent DCE studies described in
the literature to date [7, 8, 32].
Potential participants were identified via Pureprofile (https://www.pureprofile.com/au/), an
online market research company. Pureprofile was contracted to host and distribute the survey
invitation to parents on their database who had children aged between 15–19 years and resided
within Australia. Interested parents were provided with an electronic information sheet
describing the study. Parents were then asked whether they had an adolescent who would be
willing to complete the survey. Subsequent to parent and adolescent dyad consent to partici-
pate in the study, adolescents were then guided through the online survey by screen prompts.
In recognition of the time spent completing the DCE survey, account holders of adolescents
who participated received a small financial reward (AU$3.25).
Statistical analysis
The Socio-Economic Indexes for Areas, Index of Relative Socioeconomic Disadvantage 2011
(SEIFA IRSD) [45] was used to categorise socio-economic status as into tertiles: low (1st–33rd
percentile), medium (34th–66th percentile) and high (67th–100th percentile). SEIFA ranks
residential areas in Australia according to relative socio-economic disadvantage based on
information from the five-yearly Census. Student’s t-tests and χ2 tests were used to compare
means and proportions between two subgroups, respectively. Participants who failed the inter-
nal consistency test were excluded from the analysis and a sensitivity analysis was conducted
by including participants who failed the test.
DCE data were analysed using a mixed-logit model which accounts for preference hetero-
geneity. The price attribute was treated as a continuous variable and dummy-variable coding
was used for all other attributes. The model fit to the utility function was:
Uitj ¼ ðb1þ Z1iÞ life threatening illnessþ ðb2þ Z2iÞ sexually transmitted infection
þðb3þ Z3iÞ chronic illnessþ ðb4þ Z4iÞ protect you＆others
þðb5þ Z5iÞ school=university þ ðb6þ Z6iÞ GPþ ðb7þ Z7iÞ common side effects
þðb8þ Z8iÞ skin patchþ ðb9þ Z9iÞ oral doseþðb10þ Z10iÞ priceþ εitj
Uitj describes the utility of a hypothetical vaccine scenario, i derives from an individual choos-
ing alternative j in choice question t, βi is a vector of coefficients reflecting participants’ prefer-
ence for each attribute level on average, ηi indicates the individual’s specific preference (i.e. a
random effect), and εitj is a random error term describing the unmeasured variation in partici-
pants’ preferences. We assumed coefficients of all attribute levels were independent and ran-
domly distributed with a Normal distribution. A positive (negative) and significant coefficient
indicates a positive (negative) preference for a specific attribute level. The coefficient estimates
(or preference weights) can also be used to compare relative importance between different lev-
els of the same attribute or between levels of completely different attributes [11].
WTP represents a monetary measure of participants’ valuation for a change in the level of




where βcis the price coefficient and βkis the coefficient for attribute k). The pos-
itive and negative results indicate theoretically to what extent the participants and their fami-
lies would be willing to pay/to be compensated for an attribute level. The 95% confidence
intervals were estimated using the Krinsky Robb (parametric bootstrap) method [46]. WTP
estimates do not represent market prices participants and their families wanted to pay for the
various attributes of a hypothetical vaccine. All statistical analyses were performed in Stata ver-
sion 14.1 [47].
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Ethics
This study was approved by the Women’s and Children’s Health Network Human Research
Ethics Committee in Adelaide, Australia. This study has not been registered in a clinical trial
registry because it was not a clinical trial and therefore registration was not required.
Results
A total of 800 adolescents (age range 15–19 years) were enrolled and completed the survey
between December 2014 and January 2015 (S1 Dataset). Females were slightly predominant
(54.9%) in the study population. Of the participants, 90.0% were born in Australia, with
approximately 97.8% non-indigenous (Table 2). Enrolment was initially planned to be strati-
fied by state and gender. Due to difficulties in recruiting adolescent participants in smaller
states or territories such as the Northern Territory (NT) and Australian Capital Territory
(ACT), enrolment did not strictly adhere to the original regional quotas. Except for NT and
ACT, participants were reasonably representative of the adolescent population of each state.
DCE results
Participants who failed the consistency test were excluded from the analysis (N = 105, 13.1%),
generating a useable total sample of 695 adolescents (86.9%) for main DCE analysis. Except for
socio-economic status (SES) and risk taking attitudes, there were no significant differences
between the participants who passed versus those who failed the consistency test. Those who
were excluded were more likely to reside in an area with medium SES (p = 0.008) and exhib-
ited higher general (p = 0.015) and health risk attitudes (p = 0.004).
The vaccination in the case of a life threatening illness (p<0.001) had the highest preference
weight when comparing with a mild-moderate illness (Fig 1 and Table 3). Changing vaccina-
tion targeting from a mild-moderate illness to a life threatening illness could yield 17 times
(2.314 0.135) as much as utility as changing from “rare but serious” to “common but mild
and resolving” side effects. Other stronger preferences were observed for vaccination treating a
chronic illness (p<0.001) and a sexually transmitted infection (p<0.001) with common but
mild and resolving side effects (p = 0.004) and delivery via a skin patch or oral dose (p<0.001)
compared with their reference levels. Despite the success of adolescent school-based vaccina-
tion, participants were more willing to be vaccinated by GPs (p<0.001). Lower price vaccina-
tions were also preferred (p<0.001).
With the exception of one coefficient (for vaccination protecting you and others
(p = 0.274)), the standard deviations (SDs) of other random coefficients were statistically sig-
nificant, which indicated preference heterogeneity was present for those attribute levels.
A sensitivity analysis was performed by including participants who failed the consistency
test and no significant impact was observed. Subgroup analyses were conducted with regard to
SES, risk taking attitudes and participants’ intention to be vaccinated, and the results were
broadly consistent between subgroups.
Willingness to pay
Participants suggested that they and their families would be willing to pay AU$394.28 (95%CI:
AU$348.40 to AU$446.92) more for a vaccine targeting a life threatening illness than a mild-
moderate illness, AU$37.94 (95%CI: AU$19.22 to AU$57.39) more for being vaccinated at a
family practitioner clinic than a council immunisation clinic, AU$23.01 (95%CI: AU$7.12 to
AU$39.24) more for common but mild and resolving side effects than rare but serious side
Assessing vaccine preferences in adolescents
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effects, and AU$51.80 (95%CI: AU$30.42 to AU$73.70) more for delivery via a skin patch than
injection (Table 4).
Discussion
This DCE has identified preferences of Australian adolescents for immunisations providing
protection against a life threatening illness, causing common but mild and resolving side
effects, being administered by a medical practitioner and delivered via a skin patch at a lower
price. To our knowledge this is the first study to investigate adolescent preferences for immu-
nisation delivery using a DCE design. Because comparable data are lacking, we have reviewed
literature for DCE studies associated with a specific vaccine in both parental and adolescent
populations.
Fatal diseases were the most vital decisive factor in adolescent vaccine acceptance. Another
DCE study reported people valued prevention targeting a serious illness higher than cure [48].
This suggests that vaccines targeted towards a fatal illness could achieve high and sustainable
vaccine coverage, for example, adolescent vaccines for meningococcal disease. Given the
National HPV Vaccination Program started almost ten years ago [49], somewhat surprisingly,
our study participants were not strongly in favour of STI vaccines which may indicate lack of
awareness of HPV being a STI. Parental studies reported similar results that a sexual mode of
transmission had minimal impact on STI vaccine acceptability [27, 28]. Moreover, only 13% of
Table 2. Demographic characteristics of the study population.
All (N = 800) Participants who passed
the consistency test only
(N = 695)




Mean SD Mean SD Mean SD
Age (years) 17.10 1.42 17.11 1.42 17.08 1.39 0.839
Household Size (people) 4.09 1.41 4.05 1.35 4.30 1.77 0.088
Risk attitudes
In general 5.20 2.32 5.12 2.26 5.71 2.64 0.015
For health 4.11 2.61 4.01 2.53 4.79 3.00 0.004
N % N % N %
Gender
Male 361 45.13 317 45.61 44 41.90 0.477
Female 439 54.88 378 54.39 61 58.10
Completed High School 445 55.63 391 56.26 54 51.43 0.353
Born in Australia 720 90.00 629 90.50 91 86.67 0.222
Aboriginal or Torres Strait Islander 17 2.13 16 2.30 1 0.95 0.371
Socio-economic Status
Low (1st–33rd percentile) 203 25.50 183 26.48 20 19.05 0.008
Medium (34th–66th percentile) 252 31.66 205 29.67 47 44.76
High (67th–100th percentile) 341 42.84 303 43.85 38 36.19
State
NSW 257 32.13 224 32.23 33 31.43 0.224
VIC 201 25.13 173 24.89 28 26.67
QLD 166 20.75 149 21.44 17 16.19
SA 70 8.75 55 7.91 15 14.29
WA 79 9.88 68 9.78 11 10.48
TAS 16 2.00 16 2.30 0 0.00
ACT & NT 11 1.38 10 1.44 1 0.95
https://doi.org/10.1371/journal.pone.0181073.t002
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Fig 1. Preference weights for nonmonetary attributes. † Reference (omitted) level for each attribute.
https://doi.org/10.1371/journal.pone.0181073.g001
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adolescent girls were concerned about HPV in an HPV study conducted in the United States
[7]. Perceived transmission risks or severity of STI might be quite low in adolescents, which
resulted in a relatively lower estimated coefficient on STI compared to life threatening and
chronic illnesses. Although previous research indicated participants’ choices to vaccinate were
not sensitive to the probability of disease [35], assumptions made by participants about the
incidence of the disease prevented might influence their preferences. The results of disease
severity may be interpreted with caution, for example, we cannot definitively conclude that
adolescents indicated they and their families would be willing to pay AU$394 more for a vac-
cine against a life-threatening but potentially very rare disease, as compared with a mild-mod-
erate, but common one. Further research may be warranted to tease out the effects of the
disease incidence versus disease severity.
Adolescent immunisation preferences were also influenced by the severity of potential side
effects. Previous research only assessed impact of the frequency of severe reactions [9, 30, 33,
34]. Our study compared preferences between two common occurrences of side effects: rare
Table 3. Mixed logit estimates on vaccination preferences.
Attributes Coefficient SE P value SD SE P value
Disease targeted
Mild-moderate illness a
Life threatening illness 2.314 0.126 <0.001 1.909 0.135 <0.001
Sexually transmitted infection 0.437 0.092 <0.001 1.408 0.101 <0.001
Chronic illness 0.918 0.078 <0.001 0.418 0.178 0.019
Target for protection
Individual a
Individual and others 0.062 0.040 0.126 0.113 0.103 0.274
Location of vaccination
Council immunisation clinic a
School/university 0.172 0.056 0.002 0.267 0.125 0.033
GP 0.223 0.057 <0.001 0.290 0.120 0.016
Potential for side effects
Rare but serious a
Common but mild and resolving 0.135 0.047 0.004 0.558 0.067 <0.001
Vaccine delivery mechanism
Injection a
Skin patch 0.304 0.063 <0.001 0.566 0.091 <0.001
Oral dose 0.283 0.062 <0.001 0.302 0.127 0.018
Price -0.006 <0.001 <0.001 0.006 <0.001 <0.001
Log likelihood -3893.719
Number of participants b 695
Number of observations c 16680
Notes: SE—standard errors. SD—standard deviation. For all random coefficients, normal distribution was used. Price attribute was included as a
continuous variable; all other attributes were dummy coded.
a Reference (omitted) level for each attribute
b A total of 800 adolescents completed the survey. Participants who failed the consistency test (N = 105) were excluded from the main analysis reported in
this table.
c In total, 16680 scenarios (2*12*695) were assessed, with 12 choice sets per participant and each consisting of a choice between two alternative
vaccination programs (A and B).
https://doi.org/10.1371/journal.pone.0181073.t003
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but serious versus common but mild. Compared to the frequency, the severity of side effects
may play a more important role in the decision making process.
Although participants still showed positive preferences for the school or university, GP clin-
ics were their stronger location preference in our study. In Australia, adolescent school-based
vaccination has demonstrated advantages over community or private sectors and achieved a
higher coverage rate [1]. However, a lack of awareness or miscommunication might affect
their preference for school-based vaccination. More chances to communicate with GPs and
understanding benefits and risks of the vaccination might explain why participants preferred
GP clinics in our study. Similar to our finding, a varicella vaccination study reported that the
provision of vaccination at schools did not affect parents’ choices whether or not to immunise
their child [31].
Our study also found that price was an important attribute driving preferences which is in
line with previous research [9, 11, 31, 50, 51]. Recommended but non-publicly funded vaccines
were more likely to be refused by parents due to the price [50]. If a vaccine was not included
on the National Immunisation Program Schedule, vaccine prices would definitely be a finan-
cial barrier to successful implementation of an immunisation program. Although adolescents
usually would not have any income or direct out-of-pocket costs for their medical care, a DCE
study assessing WTP for a meningococcal B vaccine in Australia found a consistent pattern of
results at all attributes and levels between adolescents and adults [12]. That financial barrier
would still affect adolescent actual decision making when it comes to receipt of vaccines.
Table 4. Willingness to pay (AU$) for vaccination (based on mixed logit estimates).
Attributes Willingness to pay (AU$) 95%CI
Disease targeted
Mild-moderate illness a
Life threatening illness 394.28 348.40, 446.92
Sexually transmitted infection 74.43 44.10, 106.37
Chronic illness 156.35 129.76, 185.55
Target for protection
Individual a
Individual and others 10.53 -3.29, 24.52
Location of vaccination
Council immunisation clinic a
School/university 29.33 10.70, 48.54
GP 37.94 19.22, 57.39
Potential for side effects
Rare but serious a
Common but mild and resolving 23.01 7.12, 39.24
Vaccine delivery mechanism
Injection a
Skin patch 51.80 30.42, 73.70
Oral dose 48.25 27.95, 69.82
Number of observations 16680
Notes: Confidence interval (CI) was calculated based on the Krinsky and Robb bootstrap method (with
10,000 replications). Price attribute was included as a continuous variable; all other attributes were dummy
coded.
a Reference (omitted) level for each attribute.
https://doi.org/10.1371/journal.pone.0181073.t004
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The strength of this study is identification of adolescent preferences for immunisation pro-
grams using a DCE survey, which allows us to investigate multiple factors influencing vaccina-
tion decision and trade-off between attribute levels. Based on a large national sample of
adolescents, our study produced meaningful and robust estimates. There were some limita-
tions to our study. Prior qualitative work was not conducted to select attributes and levels. It is
possible that some potentially important attributes were omitted from the design of this study
(e.g. disease incidence). Since preferences were measured to establish which components
define the most preferred vaccine program from an adolescent perspective, an opt-out option
was not provided and participants were forced to choose between two alternatives. Whilst it
may be argued that including an opt-out option might reflect the decisions of participants in
real-life settings, the opt-out option might be selected by participants to avoid making difficult
trade-offs on attribute levels, thereby decreasing the precision of parameter estimates [52].
However, the inclusion of an opt-out option may provide more information about trade-offs
between vaccination and no vaccination. Furthermore the opt-out option would have enabled
the prediction of probabilities of take-up of different vaccine scenarios [17, 31] and might cor-
rect the WTP value for the probability of people opting out [53]. Further research is required
to explore the implications of including an opt-out option in this context. Their identification
and vaccination status cannot be verified, which may affect internal validity of the study. As
our participants were adolescents who might not be financially independent, the WTP values
in our study are a mix of personal values and perception of what their family would sacrifice
and therefore WTP may not be interpreted in the conventional way. Finally, since this is a sur-
vey-research study and only participants with internet access could be enrolled, the sample
may not be entirely representative of the general population of adolescents due to a higher per-
centage of adolescents from areas of high/medium SES with higher educational levels.
Understanding barriers and facilitators to immunisation is an important step to improve
the uptake of adolescent immunisation. Our study showed adolescents’ vaccine decisions were
driven by disease types, healthcare facilities where vaccines were administered, severity of side
effects and vaccine delivery methods. The study results can provide useful information on ado-
lescent views, values and preferences for vaccination to health authorities, vaccine providers,
immunisation educators and healthcare providers. Strategies to increase immunisation uptake
among adolescents may include providing adolescent-tailored education programs, lowering
out-of-pocket costs, and offering vaccinations outside of schools in “complementary” settings
(e.g. GP clinics). This study evaluating adolescent preferences for immunisation may be used
to inform any future health economic studies for individual vaccines before they are publicly
available. For example, the predicted high rates of vaccination against fatal illnesses, may posi-
tively affect outcomes of health economic evaluation. Our study results may also be used to
develop adolescent specific immunisation education programs. When designing an education
program for adolescent immunisation, these factors, particularly the relative severity of the dis-
ease, should be clearly explained to adolescents.
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